Drugs / CC312
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07193810 | Sep 2025 → Sep 2027 expected | idiopathic inflammatory myopathy, systemic lupus erythematosus, systemic sclerosis | CytoCares Inc | Recruiting | No outcome recorded |
| Phase 0 | NCT06888960 | Nov 2024 → Nov 2026 expected | autoimmune hemolytic anemia, idiopathic inflammatory myopathy, primary thrombocytopenia, rheumatoid arthritis +2 | CytoCares Inc | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07177911 | Sep 2025 → Sep 2027 expected | systemic lupus erythematosus | CytoCares Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06037018 | Aug 2023 → Mar 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | CytoCares Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | CytoCares Inc | Results 惠和生物T细胞三抗研究成果在国际杂志上发表 cytocares.com ↗
结果发现具有共刺激域的三抗具有更强的 T 细胞活化和记忆 T 细胞分化能力，比 BiTE-CD19xCD3 双抗诱导肿瘤细胞裂解的速度更快，具有更有效的抗肿瘤活性。 |
| 2023-03-10 | CytoCares Inc | Regulatory 国内首个基于CD28共刺激信号的三特异性抗体CC312冻干粉针剂获NMPA临床试验许可 cytocares.com ↗
CC312冻干粉针剂获批得NMPA临床试验许可 （受理号：CXSL2200621）， 适应症为复发/难治性CD19阳性B细胞恶性血液肿瘤。 |
| 2022-05-16 | CytoCares Inc | Regulatory 迈百瑞祝贺惠和生物三特异性抗体 CC312 临床试验申请获得 FDA 批准 cytocares.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | CytoCares Inc | 惠和生物T细胞三抗研究成果在国际杂志上发表 cytocares.com ↗ |
| 2023-03-10 | CytoCares Inc | 国内首个基于CD28共刺激信号的三特异性抗体CC312冻干粉针剂获NMPA临床试验许可 cytocares.com ↗ |
| 2022-05-16 | CytoCares Inc | 迈百瑞祝贺惠和生物三特异性抗体 CC312 临床试验申请获得 FDA 批准 cytocares.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07177911 ↗ |
| Modality | Other / unclassified | “CC312 is a trispecific T cell engager (TriTE)” NCT06888960 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06037018 ↗ |
| Target | CD19 | “targets the B cell surface antigen CD19” NCT06888960 ↗ |